Logo of brjopthalBritish Journal of OphthalmologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Br J Ophthalmol. 2001 Oct; 85(10): 1163–1166.
PMCID: PMC1723731

The effect on intraocular pressure of latanoprost once or four times daily


AIMS—To compare the effect on intraocular pressure (IOP) of latanoprost applied once daily with four times daily and to study if the difference persisted when treatment changed to once daily.
METHODS—IOP was followed in 28 healthy volunteers in a double masked randomised 52 day study. Latanoprost 50 µg/ml was administered once daily in one eye and four times daily in the other during 2 weeks. Subsequently both eyes received one daily drop for 2 weeks. After another 3 weeks without treatment, a single drop was instilled in each eye.
RESULTS—The IOP reduction on days 2 and 3 was greater in the eyes treated with four daily doses (p<0.01). During the following period there were no statistically significant differences between the eyes. After 3 weeks without treatment the IOP was lower than pretreatment (p<0.001). A single dose of latanoprost on day 50 resulted in a similar decrease in IOP in both eyes. Transient photophobia, mild flare, and/or a few cells occurred in 15 subjects. Two subjects were withdrawn because of photophobia and/or signs of anterior uveitis.
CONCLUSION—Latanoprost four times daily caused an IOP reducing effect which was similar to once daily dosing, except for the first 2 days of treatment when it was more effective. Transient photophobia, cells, and flare were common during the four dose regimen, but resolved spontaneously without cessation of treatment.

Full Text

The Full Text of this article is available as a PDF (133K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995 Dec;102(12):1743–1752. [PubMed]
  • Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996 Jan;103(1):138–147. [PubMed]
  • Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996 Jan;103(1):126–137. [PubMed]
  • Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993 Sep;100(9):1297–1304. [PubMed]
  • Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology. 1993 Sep;100(9):1305–1311. [PubMed]
  • Alm A, Widengård I, Kjellgren D, Söderström M, Friström B, Heijl A, Stjerschantz J. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995 Jan;79(1):12–16. [PMC free article] [PubMed]
  • Lindén C, Alm A. Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes. Acta Ophthalmol Scand. 1997 Aug;75(4):412–415. [PubMed]
  • Lindén C, Alm A. Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Curr Eye Res. 1998 Jun;17(6):567–572. [PubMed]
  • Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, Bito LZ, Podos SM. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol. 1992 Dec;110(12):1733–1738. [PubMed]
  • Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology. 1993 Sep;100(9):1312–1317. [PubMed]
  • Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med. 1987 Jun 4;316(23):1440–1444. [PubMed]
  • Lütjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 1988 Nov;47(5):761–769. [PubMed]
  • Tamm E, Rittig M, Lütjen-Drecoll E. Elektronenmikroskopische und immunhistochemische Untersuchungen zur augendrucksenkenden Wirkung von Prostaglandin F2 alpha. Fortschr Ophthalmol. 1990;87(6):623–629. [PubMed]
  • Weinreb RN, Kashiwagi K, Kashiwagi F, Tsukahara S, Lindsey JD. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997 Dec;38(13):2772–2780. [PubMed]
  • Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998 Aug;67(2):179–191. [PubMed]
  • Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, Michael AJ, Realini T, Warwar R. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998 Jul;126(1):37–41. [PubMed]
  • Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998 Feb;105(2):263–268. [PubMed]
  • Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999 Dec;77(6):668–672. [PubMed]

Figures and Tables

Figure 1
Mean IOP reduction with baseline as reference during treatment with latanoprost 50 µg/ml one or four times daily and follow up. Treatments are indicated in the lower part of the figure. Open squares represent eyes that started with once ...

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Group


Save items

Related citations in PubMed

See reviews...See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...